Capricor touts long-term efficacy of DMD therapy ahead of FDA application [Yahoo! Finance]
Capricor Therapeutics, Inc. (CAPR)
Last capricor therapeutics, inc. earnings: 3/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
capricor.com/investors
Company Research
Source: Yahoo! Finance
data from the Phase II HOPE-2 open-label extension (OLE) trial for its Duchenne muscular dystrophy (DMD) cell therapy, deramiocel. Last week, the company started rolling submissions for a biologics license application (BLA) for deramiocel as a treatment for DMD cardiomyopathy with the US Food and Drug Administration (FDA), with plans to complete the submission by the end of the year. “These results are extremely impactful for patients living with DMD as they showed sustained cardiac and skeletal muscle benefits after three years of continuous treatment with deramiocel, which underscores the potential long-term efficacy this therapy can offer,” said the company's CEO Linda Marbán. “We have been working closely with the FDA to move deramiocel towards potential approval as quickly as possible because once heart function is lost, it is unlikely to be restored. We expect deramiocel to be a lifelong treatment, with an infusion delivered quarterly,” added Marbán. The HOPE-2 OLE study
Show less
Read more
Impact Snapshot
Event Time:
CAPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CAPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CAPR alerts
High impacting Capricor Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CAPR
News
- Deramiocel's Promise Brightens Capricor's Outlook, With Strings Attached [Seeking Alpha]Seeking Alpha
- Capricor Therapeutics to Present at Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Capricor Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswire
- Capricor wins key EU designations for the lead asset [Seeking Alpha]Seeking Alpha
- Parent Project Muscular Dystrophy Culminates 30th Anniversary with Celebratory "Investing in Every Future" Event [Yahoo! Finance]Yahoo! Finance
CAPR
Earnings
- 11/13/24 - Miss
CAPR
Sec Filings
- 12/16/24 - Form 4
- 12/4/24 - Form 4
- 11/14/24 - Form 10-Q
- CAPR's page on the SEC website